The preclinical biotech is developing T cell therapies for solid tumors.
San Francisco-based Lyell Immunopharma filed with the US Securities and Exchange Commission on May 25, 2021, and hopes to raise $150 million with its initial public offering (IPO).
The company is focused on overcoming barriers to T cell therapy for solid tumors, such as T cell exhaustion, using its proprietary epigenetic and genetic reprogramming technologies. It is developing its own CAR T cell therapies for solid tumors, including lead candidate LYL797 for lung and breast cancers, and partnering with companies including GlaxoSmithKline and Orca Bio.
Still in early-stage research, Lyell plans to start its first clinical trials in 2022 and recently opened a $65 million, 70,000 square foot production facility.